• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环磷酰胺及其去乙酰化衍生物(去环磷酰胺):与一些代表性β-内酰胺酶的相互作用及其对新选择的临床分离株的相关耐药模式。

CTX and its desacetyl derivative (des-CTX): interaction with some representative beta-lactamases and their related pattern of resistance to newer selected clinical isolates.

作者信息

Amicosante G, Perilli M, Felici A, Segatore B, Franceschini N, Basani F, Di Girolamo M, Oratore A

机构信息

Department of Sciences and Biomedical Technologies, Faculty of Medicine and Surgery, University of Aquila, Italy.

出版信息

Drugs Exp Clin Res. 1990;16(11):549-56.

PMID:2101778
Abstract

In this study the kinetic features of cefotaxime (CTX) and desacetyl-cefotaxime towards several representative beta-lactamases were investigated. Desacetyl-CTX was more stable to hydrolysis in comparison with cefotaxime for all the investigated enzymes. However, a cephalosporinase produced in Acinetobacter was progressively inactivated by both CTX and des-CTX. After prolonged incubation, dialysis partially restored the enzyme activity. Finally, both compounds were tested against selected resistant strains. It is concluded that des-CTX, because of either poor hydrolysis or prolonged half-life in body fluids, could contribute in vivo to the good antimicrobial properties of cefotaxime.

摘要

本研究考察了头孢噻肟(CTX)和去乙酰头孢噻肟对几种代表性β-内酰胺酶的动力学特征。对于所有研究的酶,去乙酰CTX比头孢噻肟对水解更稳定。然而,不动杆菌产生的一种头孢菌素酶可被CTX和去乙酰CTX逐步灭活。长时间孵育后,透析可部分恢复酶活性。最后,对选定的耐药菌株测试了这两种化合物。结论是,由于去乙酰CTX在体液中水解性差或半衰期长,它在体内可能有助于头孢噻肟发挥良好的抗菌性能。

相似文献

1
CTX and its desacetyl derivative (des-CTX): interaction with some representative beta-lactamases and their related pattern of resistance to newer selected clinical isolates.环磷酰胺及其去乙酰化衍生物(去环磷酰胺):与一些代表性β-内酰胺酶的相互作用及其对新选择的临床分离株的相关耐药模式。
Drugs Exp Clin Res. 1990;16(11):549-56.
2
Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):21S-31S.
3
Comparative in vitro studies on cefotaxime and desacetylcefotaxime.头孢噻肟和去乙酰头孢噻肟的体外比较研究。
Drugs Exp Clin Res. 1986;12(12):953-65.
4
The in vitro antimicrobial activity of desacetylcefotaxime compared to other related beta-lactams.去乙酰头孢噻肟与其他相关β-内酰胺类药物相比的体外抗菌活性。
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):13S-20S.
5
Structure-function studies of arginine at position 276 in CTX-M beta-lactamases.CTX-M型β-内酰胺酶中276位精氨酸的结构-功能研究
J Antimicrob Chemother. 2008 Apr;61(4):792-7. doi: 10.1093/jac/dkn031. Epub 2008 Feb 14.
6
In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
Diagn Microbiol Infect Dis. 1984 Jun;2(3 Suppl):47S-53S.
7
Population analysis of susceptibility to cefotaxime and desacetyl-cefotaxime in Staphylococcus and Enterobacteriaceae.
Acta Pathol Microbiol Immunol Scand B. 1985 Jun;93(3):243-7. doi: 10.1111/j.1699-0463.1985.tb02883.x.
8
Dissemination of transferable CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli in Korea.韩国产可转移CTX-M型超广谱β-内酰胺酶大肠杆菌的传播情况
J Appl Microbiol. 2005;98(4):921-7. doi: 10.1111/j.1365-2672.2004.02526.x.
9
Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.琼脂稀释法、微量稀释法和纸片洗脱法测定头孢噻肟及其代谢产物对厌氧菌协同作用的比较
J Clin Microbiol. 1986 Jun;23(6):1104-8. doi: 10.1128/jcm.23.6.1104-1108.1986.
10
Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli.头孢噻肟与去乙酰头孢噻肟联合对需氧及厌氧革兰氏阴性杆菌的抗菌活性
Drugs Exp Clin Res. 1990;16(12):629-33.

引用本文的文献

1
Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.头孢噻肟。对其抗菌活性和药代动力学特性的重新评估,以及对其每日两次给药治疗轻至中度感染时的治疗效果的综述。
Drugs. 1997 Mar;53(3):483-510. doi: 10.2165/00003495-199753030-00009.